Sal-miR-58 Inhibits Ang II-Induced Inflammation in VSMCs
(A) Western blot analysis for NF-κB p50 expression. (B)Western blot analysis for NF-κB p65 expression.(C) Relative expression of IL-6, TNF-α, and IL-1β mRNA was examined by qRT-PCR and presented after normalizing to 18S rRNA (mean ± SEM; n = 3). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 versus 0 h Ang II. (D) Relative expression of IL-6, TNF-α, and IL-1β mRNA was examined by qRT-PCR and presented after normalizing to 18S rRNA (mean ± SEM; n = 3). ∗∗p < 0.01, ∗∗∗p < 0.001 versus 0 M Ang II.(E ) ELISA analysis of IL-1β, IL-6, or TNF-α in the culture medium of VSMCs. ∗∗p < 0.01, ∗∗∗p < 0.001 versus 0 h Ang II (n = 3). (F) ELISA analysis of IL-1β, IL-6, or TNF-α in the culture medium of VSMCs. ∗∗p < 0.01, ∗∗∗p < 0.001 versus 0 M Ang II (n = 3). (G) Sal-miR-58 was determined by qRT-PCR in VSMCs transfected with Sal-miR-58. ∗∗∗p < 0.001 versus miR-Ctl (n = 3). (H) qRT-PCR detected Sal-miR-58 in VSMCs transfected with Sal-miR-58 after treatment with sodium periodate. ∗∗∗p < 0.001 versus miR-Ctl+Unoxidized (n = 3). (I) VSMCs were treated with Ang II alone or combined with Sal-miR-58 for 24 h, and the expression of NF-κB p65 and p50 was examined by western blotting. (J) Relative expression of IL-6, TNF-α, and IL-1β mRNA was determined by qRT-PCR in VSMCs treated as in (I) and presented after normalizing to 18S rRNA. ∗∗p < 0.01, ∗∗∗p < 0.001 versus miR-Ctl; ###p < 0.001 versus miR-Ctl+Ang II (n = 3). (K) Levels of IL-1β, IL-6, and TNF-α were determined by ELISA in the culture medium of VSMCs treated as in (I). ∗∗p < 0.01, ∗∗∗p < 0.001 versus miR-Ctl; ##p < 0.01, ###p < 0.001 versus miR-Ctl+Ang II (n = 5).